Management of EGFR Mutant NSCLC Patients and Future Directions (excluding Resistance to EGFR TKIs)
Roy S. Herbst, MD, PhD, FACP, FASCO
Management of Metastatic Disease Using Interventional Radiology in 2023: Y90 SirSpheres and Other Procedures
Timothy Yates, MD
Most Common Adverse Events of Checkpoint Inhibitors | Current Recommendations and Management
Meri Tarockoff, MD
Immunotherapy in Advanced NSCLC: Initial Therapy and How to Overcome Resistance
George Simon, MD, FACP, FCCP
